Cowen & Co. analyst Marc Frahm maintained a Buy rating on Gritstone Oncology Inc (GRTS) today. The company’s shares opened today at $11, close to its 52-week low of $9.66.
According to TipRanks.com, Frahm is a 3-star analyst with an average return of 6.2% and a 61.8% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Odonate Therapeutics Llc, and Unum Therapeutics Inc.
Currently, the analyst consensus on Gritstone Oncology Inc is a Strong Buy with an average price target of $20.67.
See today’s analyst top recommended stocks >>
Based on Gritstone Oncology Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $17.34 million. In comparison, last year the company had a GAAP net loss of $9.45 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.
